Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hayat Pharmaceutical Industries CoAMM:HPIC -0.31%46 Earnings Yield (Joel Greenblatt) % is 11.17% as of Jun. 2026, which is 34% below its 10-year median of 16.88. GuruFocus rates AMM:HPIC with a GF Score™ of 46/100. The stock has 8 warning signs investors should review. Among 1,009 Drug Manufacturers companies, Hayat Pharmaceutical Industries Co ranks better than 84.34% on this metric.
The historical rank and industry rank for Hayat Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
AMM:HPIC'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.63 Med: 16.88 Max: 30.78
Current: 10.93
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Hayat Pharmaceutical Industries Co was 30.78%. The lowest was 7.63%. And the median was 16.88%.
AMM:HPIC's Earnings Yield (Joel Greenblatt) % is ranked better than 84.34% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.08
vs AMM:HPIC: 10.93
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Hayat Pharmaceutical Industries Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 6.17%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Hayat Pharmaceutical Industries Co (AMM:HPIC) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hayat Pharmaceutical Industries Co Earnings Yield (Joel Greenblatt) % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Hayat Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hayat Pharmaceutical Industries Co Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hayat Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Hayat Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) % falls into.
Hayat Pharmaceutical Industries Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Hayat Pharmaceutical Industries Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was JOD2.92 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 11.17% mean?
Hayat Pharmaceutical Industries Co (AMM:HPIC) has a Earnings Yield (Joel Greenblatt) % of 11.17% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Hayat Pharmaceutical Industries Co and its competitors. This is 34% below median its historical median of 16.88. Over the past decade, Hayat Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) % has ranged from 7.63 to 30.78. According to the industry distribution chart, Hayat Pharmaceutical Industries Co ranks #158 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 15.7%.
Is Hayat Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) % too high?
Hayat Pharmaceutical Industries Co's current Earnings Yield (Joel Greenblatt) % of 11.17% is 34% below median its 10-year median of 16.88. Over the past 10 years, this metric has ranged from a low of 7.63 to a high of 30.78. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.08. Hayat Pharmaceutical Industries Co's value of 11.17% is 262.7% above this industry median. Based on the distribution chart, Hayat Pharmaceutical Industries Co ranks #158 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hayat Pharmaceutical Industries Co has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Hayat Pharmaceutical Industries Co's Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hayat Pharmaceutical Industries Co ranks #158 out of 1009 companies for Earnings Yield (Joel Greenblatt) %. This places Hayat Pharmaceutical Industries Co in the top 16% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.08. Hayat Pharmaceutical Industries Co's value of 11.17% is 262.7% above this benchmark. Historically, Hayat Pharmaceutical Industries Co's own Earnings Yield (Joel Greenblatt) % has ranged from 7.63 to 30.78 over the past decade. While the company's 10-year median is 16.88 vs. the industry median of 3.08, Hayat Pharmaceutical Industries Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.08, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hayat Pharmaceutical Industries Co's current Earnings Yield (Joel Greenblatt) % of 11.17% is 262.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Hayat Pharmaceutical Industries Co and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hayat Pharmaceutical Industries Co's current Earnings Yield (Joel Greenblatt) % is 11.17%, which is 34% below median its own 10-year median of 16.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hayat Pharmaceutical Industries Co stock overvalued right now?
Hayat Pharmaceutical Industries Co (AMM:HPIC) has a current Earnings Yield (Joel Greenblatt) % of 11.17%. The current Earnings Yield (Joel Greenblatt) % is 11.17%, which is 34% below median its 10-year median of 16.88 and 262.7% above the Drug Manufacturers industry median of 3.08. Hayat Pharmaceutical Industries Co's overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Hayat Pharmaceutical Industries Co (AMM:HPIC), the current Earnings Yield (Joel Greenblatt) % is 11.17% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hayat Pharmaceutical Industries Co is a Jordan based pharmaceutical manufacturing company. The princapal activity is producing human and veterinary medicines in all its forms and medical stickers and stockings, in addition to the production of medical supplies, body care lotions, cosmetics, sutures and initiating marketing campgains as well as import and export operations. Its products include Cardiovascular system, Infectious disease, Dermatology, Gastrointestinal system, Inner Ear & Balance, Men's Health, Neurology, Vitamins & Supplements, Women's Health, and Respiratory system. The operations business operating within one geographic sector which is the Hashemite Kingdom of Jordan.
46GF Score
Get the complete analysis for AMM:HPIC
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:HPIC has been successfully added to your 
